top of page

We Work For Health Statement on IPAY 2028 Selected Drugs

We Work For Health Executive Director Dan Leonard issued the following statement in response to the Center for Medicare & Medicaid Services’ (CMS) announcement of the next selection of drugs in Medicare to be negotiated under the Inflation Reduction Act (IRA):

 

“As the Administration continues to add drugs to this list, it reinforces a troubling path driven by misguided and flawed efforts to advance government price controls under the Inflation Reduction Act. This trend is further evidenced by a troubling increase in Washington’s interest in expanding its influence over business practices and exerting greater control over pricing. These efforts carry serious consequences for biopharmaceutical innovation, American jobs and local economies, and, most importantly, patients who depend on medical breakthroughs.

 

“We Work For Health has repeatedly sounded the alarm on the dangers of government-imposed prescription drug price controls. These policies threaten to dismantle the innovation ecosystem that has taken decades to build and has positioned the U.S. as the global leader in the life sciences. Research shows this erosion is already underway and will only accelerate under the IRA’s deeply flawed framework.

 

“What we know is clear: price controls do not work. The IRA is already contributing to higher premiums for seniors, meaning Medicare beneficiaries are seeing no meaningful savings – even in the near term.

 

“America’s leadership in medical innovation is being undermined, not only by harmful policies like the IRA and the Most Favored Nation proposal, but also by increasing global competition from adversaries such as China. Government price controls weaken the infrastructure that allows American innovation to flourish, and the people who ultimately bear the greatest harm are patients.

 

“Looking ahead, We Work For Health urges policymakers to reconsider government price control policies and instead pursue solutions that protect innovation, sustain economic growth and, above all, ensure American patients have access to the cutting-edge treatments they deserve. We must prioritize policies that encourage investment in new research, maintain high-quality healthcare, truly deliver on patient savings and maintain America’s position as the global leader in medical advances.”

 

To learn more, check out We Work For Health’s resources related to the Inflation Reduction Act:

 

 

 
 
bottom of page